Human IgG1 kappa monoclonal antibody against pappalysin-1 (AstraZeneca)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameHuman IgG1 kappa monoclonal antibody against pappalysin-1 (AstraZeneca)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionPappalysin-1 inhibitors
TargetsPappalysin-1
Therapy Area/IndicationsPolycystic Kidney, Autosomal Dominant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Ab
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Ab
Inactive CompaniesN/A
Active IndicationsPolycystic Kidney, Autosomal Dominant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A